Creative Planning Takes Position in USANA Health Sciences, Inc. (NYSE:USNA)

Creative Planning purchased a new stake in USANA Health Sciences, Inc. (NYSE:USNA) in the 3rd quarter, according to its most recent disclosure with the SEC. The fund purchased 10,398 shares of the company’s stock, valued at approximately $394,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of USNA. BNP Paribas Financial Markets raised its holdings in shares of USANA Health Sciences by 18.1% in the 1st quarter. BNP Paribas Financial Markets now owns 38,820 shares of the company’s stock worth $1,883,000 after purchasing an additional 5,952 shares in the last quarter. State Board of Administration of Florida Retirement System grew its position in USANA Health Sciences by 22.7% during the first quarter. State Board of Administration of Florida Retirement System now owns 8,430 shares of the company’s stock valued at $409,000 after purchasing an additional 1,560 shares in the last quarter. BOKF NA grew its position in USANA Health Sciences by 274.5% in the first quarter. BOKF NA now owns 2,771 shares of the company’s stock worth $133,000 after acquiring an additional 2,031 shares in the last quarter. Price T Rowe Associates Inc. MD grew its position in USANA Health Sciences by 9.2% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,849 shares of the company’s stock worth $284,000 after acquiring an additional 494 shares in the last quarter. Finally, Jacobs Levy Equity Management Inc. grew its position in USANA Health Sciences by 2.6% in the first quarter. Jacobs Levy Equity Management Inc. now owns 111,492 shares of the company’s stock worth $5,407,000 after acquiring an additional 2,820 shares in the last quarter. 54.25% of the stock is owned by institutional investors and hedge funds.

USANA Health Sciences Trading Up 0.4 %

USNA opened at $40.50 on Friday. The stock has a market capitalization of $771.61 million, a PE ratio of 14.31, a PEG ratio of 1.29 and a beta of 0.89. USANA Health Sciences, Inc. has a 1-year low of $34.15 and a 1-year high of $54.81. The firm has a 50-day moving average price of $37.52 and a two-hundred day moving average price of $42.06.

USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, October 22nd. The company reported $0.56 EPS for the quarter, topping the consensus estimate of $0.49 by $0.07. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.64%. The company had revenue of $200.22 million during the quarter, compared to analysts’ expectations of $208.45 million. During the same quarter in the previous year, the company earned $0.59 EPS. On average, research analysts predict that USANA Health Sciences, Inc. will post 2.45 EPS for the current year.

Insider Transactions at USANA Health Sciences

In other news, Director Gilbert A. Fuller sold 675 shares of USANA Health Sciences stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Gilbert A. Fuller sold 675 shares of the business’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $37.71, for a total transaction of $25,454.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Paul A. Jones sold 6,266 shares of the business’s stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The disclosure for this sale can be found here. 0.33% of the stock is owned by corporate insiders.

Analysts Set New Price Targets

A number of research firms recently issued reports on USNA. DA Davidson lowered their target price on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating on the stock in a research note on Wednesday, October 23rd. StockNews.com downgraded shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 24th.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.